Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Zevra Therapeutics has received a consensus recommendation of "Moderate Buy" from seven ratings firms, with six analysts suggesting a buy and one a hold.
• The average price target among analysts for Zevra Therapeutics is $24.00, with recent reports showing varying price targets from $18.00 to $29.00.
• Insider trading activity is noted, with Director John B. Bode purchasing 5,000 shares, increasing his holdings to 45,000 shares valued at approximately $412,200.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $24.00.

ZVRA has been the subject of several recent research reports. HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 target price for the company. Cantor Fitzgerald lifted their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a report on Thursday, July 10th. Zacks Research downgraded shares of Zevra Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, August 18th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Finally, JMP Securities lowered their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating on the stock in a report on Wednesday, August 13th.

Insider Activity at Zevra Therapeutics

In related news, Director John B. Bode purchased 5,000 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were purchased at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the acquisition, the director owned 45,000 shares in the company, valued at approximately $412,200. This trade represents a 12.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Woodline Partners LP grew its holdings in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock worth $34,571,000 after purchasing an additional 476,032 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Zevra Therapeutics in the fourth quarter worth about $53,000. Millennium Management LLC lifted its stake in Zevra Therapeutics by 138.2% in the fourth quarter. Millennium Management LLC now owns 233,132 shares of the company's stock worth $1,944,000 after acquiring an additional 135,246 shares during the period. Deutsche Bank AG lifted its stake in Zevra Therapeutics by 25.4% in the fourth quarter. Deutsche Bank AG now owns 50,906 shares of the company's stock worth $425,000 after acquiring an additional 10,306 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in Zevra Therapeutics in the fourth quarter worth about $145,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $9.77 on Friday. The company has a 50 day moving average price of $9.64 and a 200-day moving average price of $8.94. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $548.39 million, a PE ratio of -46.52 and a beta of 1.56. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.